Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clostridium novyi-NT - BioMed Valley Discoveries

Drug Profile

Clostridium novyi-NT - BioMed Valley Discoveries

Alternative Names: BVD-CNV; BVD-CNV/IT; BVD-CNV/IV; C.novyi-NT; Clostridium novyi-NT spores; Clostridium-novyi-non-toxic

Latest Information Update: 26 Jul 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioMed Valley Discoveries; Johns Hopkins University
  • Developer BioMed Valley Discoveries; M. D. Anderson Cancer Center; Merck Sharp & Dohme
  • Class Antineoplastics; Bacteria
  • Mechanism of Action Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 10 Jul 2018 Phase-I clinical trials in Solid tumours (Combination therapy, Second-line therapy or greater, Late-stage disease) in USA (Intratumoural) (NCT03435952)
  • 28 May 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (Intratumoural, Injection)
  • 16 Feb 2018 BioMed Valley Discoveries and Merck & Co. plan a phase Ib trial of pembrolizumab in combination with for intratumoral Injection of Clostridium Novyi-NT Solid tumours (Combination therapy, Second-line therapy or greater, Late-stage disease) in the US (NCT03435952)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top